PDCD1 and urinary bladder cancer: In this context, PD-1 and PD-L1 play roles in a typical immune pathway, and PD-L1 is expressed in 20–70% of patients with lung cancer [4, 21–24], urinary bladder cancer [25], malignant melanoma [26], and ovarian cancer [27].